Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in ES-SCLC
NCT05703971Phase 2Recruiting
- Sponsor
- Genprex, Inc.
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of quaratusugene ozeplasmid in small cell lung cancer (SCLC) (2 arms), sponsored by Genprex, Inc. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 21 days and Progression-Free Survival Rate at 18 weeks. Started May 2024; status: recruiting.
02
Drugs
quaratusugene ozeplasmid
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05703971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703971.